BioCardia, Inc.

NASDAQ
BCDA
Stock
Yield per half year: -7.46%
Dividend yield: 0%
Sector: Healthcare

Share chart BioCardia, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About BioCardia, Inc.

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.

more details
The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2008-03-14
ISIN US09060U5074
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 1.97
Change price per day: 0% (2.11)
Change price per week: +11.05% (1.9)
Change price per month: -30.82% (3.05)
Change price per 3 month: +3.43% (2.04)
Change price per half year: -7.46% (2.28)
Change price per year: -59.42% (5.2)
Change price per 3 year: +31.88% (1.6)
Change price per 5 year: -54.62% (4.65)
Change price per 10 year: +1 752.5% (0.1139)
Change price per year to date: -9.05% (2.32)
All parameters

Grade

Underestimation
Title Value Grade
P/S 103.13 1
P/BV 7.15 1
P/E 0 0
EV/EBITDA -0.5749 0
Total: 2.88
Efficiency
Title Value Grade
ROA, % -236.81 0
ROE, % 2074.67 10
Total: 1.67
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 1.43
Debt
Title Value Grade
Debt/EBITDA -0.1199 10
Total: 8.8
Growth impulse
Title Value Grade
Yield Revenue, % -60 0
Yield Ebitda, % -48.48 0
Yield EPS, % 95.67 9
Total: 1.8
More

Main owners

Institutions Volume Share, %
CM Management, LLC 700 000 14.44
Vanguard Group Inc 650 763 13.42
Geode Capital Management, LLC 159 648 3.29
Renaissance Technologies, LLC 88 300 1.82
Family Management Corporation 77 500 1.6
Susquehanna International Group, LLP 65 426 1.35
Blackrock Inc. 42 767 0.88
Virtu Financial LLC 41 348 0.85
Citadel Advisors Llc 33 629 0.69
Brown Advisory Inc. 33 085 0.68

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Peter A. Altman Ph.D. CEO, President & Director 515.51k 1967 (58 years)
Mr. David McClung Chief Financial Officer 370.86k 1963 (62 years)
Mr. Edward M. Gillis Senior Vice President of Devices 263.1k 1962 (63 years)

About company

Address: United States, Sunnyvale. CA, 320 Soquel Way - Open in google maps, Open in yandex maps
Website: https://www.biocardia.com